Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402689 | 0.92 | EPHX2 (0.51) | EPHX2SMN1; SMN2NPSR1HIF1A | |
| SCHEMBL3404931 | 0.90 | EPHX2 (0.49) | EPHX2SMN1; SMN2NPSR1 | |
| SCHEMBL3406201 | 0.90 | CHEK1 (0.49) | EPHX2SMN1; SMN2NPSR1HIF1A | |
| SCHEMBL3402633 | 0.88 | EPHX2 (0.44) | EPHX2SMN1; SMN2NPSR1HIF1A | |
| SCHEMBL3407582 | 0.88 | SMN1; SMN2 (0.50) | EPHX2SMN1; SMN2NPSR1HIF1A | |
| SCHEMBL3407930 | 0.87 | ALDH1A1 (0.49) | EPHX2SMN1; SMN2NPSR1HIF1A | |
| SCHEMBL3408293 | 0.86 | SMN1; SMN2 (0.50) | EPHX2SMN1; SMN2NPSR1HIF1A | |
| SCHEMBL3403225 | 0.85 | SMN1; SMN2 (0.49) | EPHX2SMN1; SMN2NPSR1HIF1A | |
| SCHEMBL3267206 | 0.78 | HIF1A (0.57) | SMN1; SMN2HIF1ACYP2D6CYP2C19 | |
| SCHEMBL3402970 | 0.77 | HIF1A (0.51) | HIF1ACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254666-A1 | 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-12-01 | — | — | EP | claimed |
| WO-2009112395-A1 | 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-17 | — | — | WO | claimed |
| US-8350028-B2 | 2-aminoquinolines | HOFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2254666-A1 | 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009112395-A1 | 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233927-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233927-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | EPHX2 3686/4885SMN1; SMN2 1126/4885NPSR1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.